E
Edward Abraham
Researcher at Dalhousie University
Publications - 173
Citations - 13258
Edward Abraham is an academic researcher from Dalhousie University. The author has contributed to research in topics: Lung injury & Medicine. The author has an hindex of 50, co-authored 155 publications receiving 12702 citations. Previous affiliations of Edward Abraham include University of California, Los Angeles & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.
Howard L. Corwin,Andrew Gettinger,Ronald G. Pearl,Mitchell P. Fink,Mitchell M. Levy,Edward Abraham,Neil R. MacIntyre,M. Michael Shabot,Mei-Sheng Duh,Marc J. Shapiro +9 more
TL;DR: The number of RBC transfusions a patient received during the study was independently associated with longer ICU and hospital lengths of stay and an increase in mortality and a nadir hemoglobin level of <9 g/dL was a predictor of increased mortality and length of stay.
Journal ArticleDOI
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Charles J. Fisher,Jan M. Agosti,Steven M. Opal,Stephen F. Lowry,Robert A. Balk,Jerald C. Sadoff,Edward Abraham,Roland M. H. Schein,Ernest Benjamin +8 more
TL;DR: In patients with septic shock, treatment with the TNFR:Fc fusion protein does not reduce mortality, and higher doses appear to be associated with increased mortality.
Journal ArticleDOI
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.
Edward Abraham,Konrad Reinhart,Steven M. Opal,Ignace Demeyer,Christopher J. Doig,Angel López Rodriguez,Richard Beale,Petr Svoboda,Pierre-François Laterre,Stuart Simon,Bruce Light,Herbert Spapen,Judy Stone,Allan Seibert,Claus Peckelsen,Cathy De Deyne,Russell Postier,Ville Pettilä,Charles L. Sprung,Antonio Artigas,Sandra Percell,Vincent Shu,Christian Zwingelstein,Jeffrey Tobias,Lona Poole,James C. Stolzenbach,Abla A. Creasey +26 more
TL;DR: Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR and tifACogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.
Journal ArticleDOI
Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial
Edward Abraham,Richard G. Wunderink,Henry Silverman,Trish M. Perl,Stanley A. Nasraway,Howard Levy,R Bone,Richard P. Wenzel,Robert A. Balk,R Allred +9 more
TL;DR: There was no decrease in mortality between placebo and TNF-α MAb in all infused patients, and in septic shock patients who received T NF- α MAb, a significant reduction in mortality was present 3 days after infusion; however, although a trend toward reduced mortality continued at 28 days following treatment with TTFMAb, the difference in mortality among shock patients treated with placebo or TFB was not significant.
Journal ArticleDOI
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group
Steven M. Opal,Charles J. Fisher,Jean-François Dhainaut,Jean Louis Vincent,Rainer Brase,Stephen F. Lowry,Jerald C. Sadoff,Gus J. Slotman,Howard Levy,Robert A. Balk,Maire P. Shelly,John Pribble,John F. LaBrecque,Janice Lookabaugh,Hugh Donovan,Howard Dubin,Robert P. Baughman,James Norman,Eric J. DeMaria,Klaus Matzel,Edward Abraham,Michael G. Seneff +21 more
TL;DR: In this article, the authors evaluated the therapeutic efficacy and safety of recombinant human interleukin-1 receptor antagonist (rhlL-1ra) in the treatment of patients with severe sepsis.